{"i": ["glinides", "thiazolidinediones28", "carbohydrate", "sulfonylurea", "vildagliptin to nateglinide", "sulfonylureas", "nateglinide + vildagliptin", "nateliginide", "Nateglinide", "switching to vildagliptin", "Glibenclamide", "combination therapy", "nateglinide and dipeptidyl peptidase \u2010 IV ( DPP \u2010 IV ) inhibitors", "sulfonylurea compounds", "nateglinide .", "DPP \u2010 IV inhibitors", "sulfonylurea26", "placebo , glibenclamide , vildagliptin or both", "ACE , angiotensin \u2010 converting enzyme inhibitor ; ARB , angiotensin", "nateglinide to vildagliptin )", "nateglinide to vildagliptin .", "nateglinide to vildagliptin", "nateglinide", "diet therapy", "vildagliptin and nateglinide", "placebo", "glibenclamide", "Vildagliptin", "oral vildagliptin", "nateglinide and vildagliptin", "vildagliptin monotherapy without nateglinide", "nateglinide with vildagliptin", "GLP \u2010 1", "alogliptin", "nateglinide plus vildagliptin combination", "vildagliptin and sulfonylurea", "nateglinide plus vildagliptin", "nateginide", "glinide and incretin \u2010 related drugs", "vildagliptin with nateglinide", "nateglinide \u2010", "Glinides", "DPP \u2010 IV inhibitor", "Vildagliptin plus glibenclamide", "vildagliptin plus glimepiride", "vildagliptin", "vildagliptin and nateglinde"], "o": ["secretion of insulin and glucagon , serum lipid profile under standard meal load", "hypoglycemia .", "glycemic control ( HbA1c and area under the curve [ AUC ] of serum glucose", "glycemic control and insulin secretion", "insulin secretion", "insulin and C \u2010 peptide responses", "mild hypoglycemia", "rates", "active GLP \u2010 1 concentration", "mean AUC of glucose", "mean changes in area under the curve of glucose", "glucose , insulin , glucagon and lipids ( triglycerides [ TG ], low \u2010 density lipoprotein cholesterol , high \u2010 density lipoprotein cholesterol and total cholesterol )", "Mild nausea and liver dysfunction", "liver transaminases .", "mean laboratory values", "severe hypoglycemia .", "hypoglycemia \u2010 related symptoms", "reporting of adverse events", "interleukin ( IL )\u2010 6 , total adiponectin , active GLP \u2010 1 , and high \u2010 sensitivity C reactive protein ( hsCRP )", "postprandial glucose level", "glucose excursion", "plasma DPP \u2010 IV activity", "adverse events", "incidence of hypoglycemia", "serious adverse events", "mean change in ISG0 \u2013 180 min", "fasting glucose level", "AUCs of glucagon", "mean HbA1c level", "target HbA1c", "therapeutic efficacy", "overall incidence of hypoglycemia", "glycated hemoglobin", "Plasma glucose responses", "AUC of glucagon", "fasting serum glucose level", "BP", "total energy content", "AUC0 \u2013 180 min glucagon", "insulin secretory responses", "hematological , biochemical and urinary parameters", "hypoglycemic episodes .", "serum lipids ( total cholesterol , high \u2010 density lipoprotein cholesterol and triglycerides ) and HbA1c", "insulin secretion .", "AUC", "postprandial hyperglycemia", "assessment of vital signs , clinical hematology and chemistry , urinalysis", "early phase insulin secretion", "effects on blood pressure ( BP ) and body mass index ( BMI ).", "mean change in AUC0 \u2013 180 min glucose", "incidence of hypoglycemic events", "mean HbA1c", "discontinuation", "insulin secretion relative to glucose elevation ( ISG )", "mean ISG0", "mean serum glucose concentrations", "overall incidence of adverse events", "glucagon", "postprandial adiponectin , IL \u2010 6 and hsCRP", "laboratory data , BP , BMI and standard meal loading test", "Bodyweight", "HbA1c", "ISG0 \u2013 30 min", "glycemic control .", "fasting serum low \u2010 density lipoprotein cholesterol", "mean AUC0 \u2013 180 min insulin responses", "serum insulin", "severe hypoglycemia", "plasma adiponectin , BP and BMI", "hypoglycemic events", "mean AUC0 \u2013 180 min glucose", "plasma active GLP \u2010 1 concentrations", "liver enzymes", "overall insulin exposure", "mean change in HbA1c", "early \u2010 phase insulin secretion", "safety", "insulin secretion relative to glucose elevation", "serum insulin levels", "glucose levels", "general health , compliance with medications , laboratory data , blood pressure , and diet and exercise status", "AUC0 \u2013 60 min insulin", "mean change in insulin secretion relative to glucose elevation ( ISG )", "ISG0", "glycemic control", "adverse effects", "tolerated", "fasting and postprandial hyperglycemia", "lipid metabolism", "bodyweight", "liver dysfunction", "Hypoglycemic events", "overall incidence of adverse effects"]}